In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Panc 08.13 is a pancreatic adenocarcinoma epithelial cell line derived in 1995 from a primary tumor removed from the head-of-the-pancreas of a male with pancreatic adenocarcinoma. The cell line exhibits a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine. [50655] The cells have a reported plating efficiency of 40%. [50655]
ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate and supplemented with 10 Units/ml human insulin, 85%; fetal bovine serum, 15% Temperature: 37.0°C
Subculturing:
Subc*tion Ratio: A subc*tion ratio of 1:2 to 1:4 is recommended Medium Renewal: Every 2 to 3 days Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature （or at 37C） until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks.
Preservation:
culture medium 95%; DMSO, 5%
Doubling Time:
20 hrs
Related Products:
Recommended medium （without the additional supplements or serum described under ATCC Medium）:ATCC 30-2001 recommended serum:ATCC 30-2020
References:
50655: Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602
Related Links
NCBI Entrez Search
Make a Deposit
Frequently Asked Questions
Material Transfer Agreement
Technical Support
Related Cell Culture Products
ATCC® Number: CRL-2551™ Price: $417.00 Designations: Panc 08.13 Depositors: EM Jaffee Biosafety Level: 1 Shipped: frozen Medium & Serum: See Propagation Growth Properties: adherent Organism: Homo sapiens （human） Morphology: epithelial
Source: Organ: pancreas Disease: adenocarcinoma Cellular Products: cytokeratins 7 and 18 [50655] Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic: Yes Oncogene: K-ras + Antigen Expression: MHC class I +; MHC class II - [50655] DNA Profile （STR）: Amelogenin: X CSF1PO: 11 D13S317: 13 D16S539: 13 D5S818: 13,14 D7S820: 11 THO1: 6,9.3 TPOX: 8,12 vWA: 18 Age: 85 years Gender: male Ethnicity: White Comments: Panc 08.13 is a pancreatic adenocarcinoma epithelial cell line derived in 1995 from a primary tumor removed from the head-of-the-pancreas of a male with pancreatic adenocarcinoma. The cell line exhibits a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine. [50655] The cells have a reported plating efficiency of 40%. [50655] Propagation: ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate and supplemented with 10 Units/ml human insulin, 85%; fetal bovine serum, 15% Temperature: 37.0°C Subculturing: Subc*tion Ratio: A subc*tion ratio of 1:2 to 1:4 is recommended Medium Renewal: Every 2 to 3 days Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature （or at 37C） until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks. Preservation: culture medium 95%; DMSO, 5% Doubling Time: 20 hrs Related Products: Recommended medium （without the additional supplements or serum described under ATCC Medium）:ATCC 30-2001 recommended serum:ATCC 30-2020 References: 50655: Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602 Related Links NCBI Entrez Search Make a Deposit Frequently Asked Questions Material Transfer Agreement Technical Support Related Cell Culture Products
